# Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Canonical URL: https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-report-second-quarter-2026-financial-results-and-business-55ac999b
Ticker: DNLI
Company: Denali Therapeutics
Source: Denali Therapeutics
Published: 2026-07-27 20:01 EST
## Summary

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial...

## Article Body
Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.

Following the announcement, Denali's management will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss Denali’s second quarter 2026 financial results and provide a general business update.

The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of Denali's website at www.denalitherapeutics.com or by clicking here . A replay of the webcast will be archived on Denali’s website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com .

Investor Contact:

Laura Hansen

hansen@dnli.com
## Recent Company News
- 2026-07-27 20:01 EST — [Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-report-second-quarter-2026-financial-results-and-business-55ac999b) — Source: Denali Therapeutics
- 2026-07-09 20:01 EST — [Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier](https://biopharmsignal.com/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-association-i-4deb6898) — Source: Denali Therapeutics
- 2026-06-18 12:00 EST — [Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million](https://biopharmsignal.com/news/DNLI/denali-therapeutics-enters-agreement-to-sell-rare-pediatric-disease-priority-rev-0e62f7af) — Source: Denali Therapeutics
- 2026-05-21 22:00 EST — [Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease](https://biopharmsignal.com/news/DNLI/biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122--cfdf22fe) — Source: Denali Therapeutics
- 2026-05-07 20:01 EST — [Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/DNLI/denali-therapeutics-reports-first-quarter-2026-financial-results-and-business-hi-b2e6c27c) — Source: Denali Therapeutics
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)